Abstract
Trends in Within-Class Changes in US Average Wholesale Prices for Brand-Name Medications for Common Conditions From 2015 to 2020
Highlights
Several new medications for treating common chronic conditions have come to market in the US in recent years
We conducted a cross-sectional study of per-pill average wholesale prices (AWPs) in the US from August 13, 2015, to August 13, 2020, obtained the Micromedex Red Book (IBM).[3]
The median compound annual growth rates (CAGRs) in costs over this 5-year period ranged from 6.6% (3.0%-7.4%) for the 4 dipeptidyl peptidase-4 (DPP4) inhibitors to 13.5% (8.0%-19.1%) for the 2 P2Y12 inhibitors (Figure 2)
Summary
Several new medications for treating common chronic conditions have come to market in the US in recent years While such increased competition might be expected to decrease drug prices, policies promoting competition among brand-name drugs within the same class have not been associated with lower list prices.[1] an analysis of the wholesale acquisition costs of insulins from 2012 to 2016, when only branded formulations were available, demonstrated compound annual growth rates (CAGRs) in costs ranging from 15% to 17%.2. The objective of this cross-sectional study was to assess patterns in price changes for multiple brand-name medications within the same drug class existing in the US market contemporaneously. An analysis of the wholesale acquisition costs of insulins from 2012 to 2016, when only branded formulations were available, demonstrated compound annual growth rates (CAGRs) in costs ranging from 15% to 17%.2 The objective of this cross-sectional study was to assess patterns in price changes for multiple brand-name medications within the same drug class existing in the US market contemporaneously.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
